By Scott Baltic
NEW YORK (Reuters Health) - About half of patients with vitiligo who undergo autologous non-cultured melanocyte-keratinocyte transplantation (MKTP) retain substantial repigmentation of the treated areas 72 months later, a new study indicates.
In addition, although the majority of repigmentation occurred during the first six months after MKTP, about two-thirds of the areas treated continued to attain additional repigmentation for 12 or more months after treatment.
Segmental vitiligo responded better to MKTP than did nonsegmental vitiligo, but skin phototype, patient age and location of the area(s) treated had no significant effect on treatment outcomes.
“MKTP provides satisfactory long-term repigmentation in the majority of appropriately selected patients with leukoderma,” concluded the authors, a group of U.S., Thai, and Saudi Arabian researchers.
“It is possible,” they added, “that this long-term repigmentation could still be enhanced through the use of adjuvant treatments (before and/or after MKTP) and by adjusting the viable melanocyte concentrations in cell suspension.”
The single-center retrospective report was released online on May 11 in the Journal of the American Academy of Dermatology.
“Nobody knew how long” the repigmentation would last, corresponding author Dr. Iltefat Hamzavi, of Henry Ford Hospital in Detroit, Michigan told Reuters Health in a phone interview.
________________________________________________________________________
Related Content
Biomarkers Tied to Vitiligo Activity and Progression
Step Up for Vitiligo
________________________________________________________________________
The key finding is that MKTP “is a long-term option,” Dr. Hamzavi said.
His team studied 63 patients who received 75 MKTP treatments for 157 sites and for whom long-term follow-up data (median, 24 months; range, 12-72) was available.
The largest segment of the cohort was white (42%); 33% were South Asian, 10% were African-American, 6% were East Asian, 5% were Middle Eastern, and 4% were Hispanic.
Treatment outcomes were quantified by a five-point grading scale and the Vitiligo Area Scoring Index.
At 24, 48, and 72 months after MKTP, 53%, 64%, and 53% of sites, respectively, maintained at least 75% repigmentation.
Good color match was seen in most treated sites, including 76% of sites with segmental vitiligo and 85% of nonsegmental sites.
Though patients tend to hope for immediate results, Dr. Hamzavi continued, the findings indicate that patients and physicians should wait at least a year to 18 months before giving up on the results from MKTP.
Overall, he said, patients now can have more confidence that MKTP will be worth the expense and trouble, so it’s likely that more patients will be willing to undergo the two- to four-hour outpatient procedure.
Although autologous non-cultured MKTP has emerged as one of the best approaches to stable vitiligo, “The careful selection of a stable disease remains one of the prerequisites for the successful outcome of this modality,” Dr. Davinder Parsad, of the Postgraduate Institute of Medical Education and Research, Chandigarh, India, and the Dermatology University of Rome, told Reuters Health by email.
“This interesting study showed the effectiveness of this procedure in producing long-term repigmentation even at 72 months,” Dr. Parsad added, though he called for prospective long-term studies to confirm these findings.
“MKTP has provided hope for many vitiligo patients . . . as its success rate can reach up to 90% repigmentation in patients with stable disease,” Dr. Bassel Mahmoud, of the Vitiligo Clinic and Research Center at the University of Massachusetts in Worcester told Reuters Health in an email.
“This study,” he added, “emphasizes even more the efficiency of this procedure, showing that its success is not only temporary, but also extends long term (up to 72 months), leading to a high degree of patient satisfaction.”
The study was partially supported by the Shahani Foundation and Multicultural Dermatology Fund at Henry Ford Hospital.
SOURCE: https://bit.ly/2t363aT
J Am Acad Dermatol 2017.
(c) Copyright Thomson Reuters 2017. Click For Restrictions - https://about.reuters.com/fulllegal.asp
By Scott Baltic
NEW YORK (Reuters Health) - About half of patients with vitiligo who undergo autologous non-cultured melanocyte-keratinocyte transplantation (MKTP) retain substantial repigmentation of the treated areas 72 months later, a new study indicates.
In addition, although the majority of repigmentation occurred during the first six months after MKTP, about two-thirds of the areas treated continued to attain additional repigmentation for 12 or more months after treatment.
Segmental vitiligo responded better to MKTP than did nonsegmental vitiligo, but skin phototype, patient age and location of the area(s) treated had no significant effect on treatment outcomes.
“MKTP provides satisfactory long-term repigmentation in the majority of appropriately selected patients with leukoderma,” concluded the authors, a group of U.S., Thai, and Saudi Arabian researchers.
“It is possible,” they added, “that this long-term repigmentation could still be enhanced through the use of adjuvant treatments (before and/or after MKTP) and by adjusting the viable melanocyte concentrations in cell suspension.”
The single-center retrospective report was released online on May 11 in the Journal of the American Academy of Dermatology.
“Nobody knew how long” the repigmentation would last, corresponding author Dr. Iltefat Hamzavi, of Henry Ford Hospital in Detroit, Michigan told Reuters Health in a phone interview.
________________________________________________________________________
Related Content
Biomarkers Tied to Vitiligo Activity and Progression
Step Up for Vitiligo
________________________________________________________________________
The key finding is that MKTP “is a long-term option,” Dr. Hamzavi said.
His team studied 63 patients who received 75 MKTP treatments for 157 sites and for whom long-term follow-up data (median, 24 months; range, 12-72) was available.
The largest segment of the cohort was white (42%); 33% were South Asian, 10% were African-American, 6% were East Asian, 5% were Middle Eastern, and 4% were Hispanic.
Treatment outcomes were quantified by a five-point grading scale and the Vitiligo Area Scoring Index.
At 24, 48, and 72 months after MKTP, 53%, 64%, and 53% of sites, respectively, maintained at least 75% repigmentation.
Good color match was seen in most treated sites, including 76% of sites with segmental vitiligo and 85% of nonsegmental sites.
Though patients tend to hope for immediate results, Dr. Hamzavi continued, the findings indicate that patients and physicians should wait at least a year to 18 months before giving up on the results from MKTP.
Overall, he said, patients now can have more confidence that MKTP will be worth the expense and trouble, so it’s likely that more patients will be willing to undergo the two- to four-hour outpatient procedure.
Although autologous non-cultured MKTP has emerged as one of the best approaches to stable vitiligo, “The careful selection of a stable disease remains one of the prerequisites for the successful outcome of this modality,” Dr. Davinder Parsad, of the Postgraduate Institute of Medical Education and Research, Chandigarh, India, and the Dermatology University of Rome, told Reuters Health by email.
“This interesting study showed the effectiveness of this procedure in producing long-term repigmentation even at 72 months,” Dr. Parsad added, though he called for prospective long-term studies to confirm these findings.
“MKTP has provided hope for many vitiligo patients . . . as its success rate can reach up to 90% repigmentation in patients with stable disease,” Dr. Bassel Mahmoud, of the Vitiligo Clinic and Research Center at the University of Massachusetts in Worcester told Reuters Health in an email.
“This study,” he added, “emphasizes even more the efficiency of this procedure, showing that its success is not only temporary, but also extends long term (up to 72 months), leading to a high degree of patient satisfaction.”
The study was partially supported by the Shahani Foundation and Multicultural Dermatology Fund at Henry Ford Hospital.
SOURCE: https://bit.ly/2t363aT
J Am Acad Dermatol 2017.
(c) Copyright Thomson Reuters 2017. Click For Restrictions - https://about.reuters.com/fulllegal.asp
By Scott Baltic
NEW YORK (Reuters Health) - About half of patients with vitiligo who undergo autologous non-cultured melanocyte-keratinocyte transplantation (MKTP) retain substantial repigmentation of the treated areas 72 months later, a new study indicates.
In addition, although the majority of repigmentation occurred during the first six months after MKTP, about two-thirds of the areas treated continued to attain additional repigmentation for 12 or more months after treatment.
Segmental vitiligo responded better to MKTP than did nonsegmental vitiligo, but skin phototype, patient age and location of the area(s) treated had no significant effect on treatment outcomes.
“MKTP provides satisfactory long-term repigmentation in the majority of appropriately selected patients with leukoderma,” concluded the authors, a group of U.S., Thai, and Saudi Arabian researchers.
“It is possible,” they added, “that this long-term repigmentation could still be enhanced through the use of adjuvant treatments (before and/or after MKTP) and by adjusting the viable melanocyte concentrations in cell suspension.”
The single-center retrospective report was released online on May 11 in the Journal of the American Academy of Dermatology.
“Nobody knew how long” the repigmentation would last, corresponding author Dr. Iltefat Hamzavi, of Henry Ford Hospital in Detroit, Michigan told Reuters Health in a phone interview.
________________________________________________________________________
Related Content
Biomarkers Tied to Vitiligo Activity and Progression
Step Up for Vitiligo
________________________________________________________________________
The key finding is that MKTP “is a long-term option,” Dr. Hamzavi said.
His team studied 63 patients who received 75 MKTP treatments for 157 sites and for whom long-term follow-up data (median, 24 months; range, 12-72) was available.
The largest segment of the cohort was white (42%); 33% were South Asian, 10% were African-American, 6% were East Asian, 5% were Middle Eastern, and 4% were Hispanic.
Treatment outcomes were quantified by a five-point grading scale and the Vitiligo Area Scoring Index.
At 24, 48, and 72 months after MKTP, 53%, 64%, and 53% of sites, respectively, maintained at least 75% repigmentation.
Good color match was seen in most treated sites, including 76% of sites with segmental vitiligo and 85% of nonsegmental sites.
Though patients tend to hope for immediate results, Dr. Hamzavi continued, the findings indicate that patients and physicians should wait at least a year to 18 months before giving up on the results from MKTP.
Overall, he said, patients now can have more confidence that MKTP will be worth the expense and trouble, so it’s likely that more patients will be willing to undergo the two- to four-hour outpatient procedure.
Although autologous non-cultured MKTP has emerged as one of the best approaches to stable vitiligo, “The careful selection of a stable disease remains one of the prerequisites for the successful outcome of this modality,” Dr. Davinder Parsad, of the Postgraduate Institute of Medical Education and Research, Chandigarh, India, and the Dermatology University of Rome, told Reuters Health by email.
“This interesting study showed the effectiveness of this procedure in producing long-term repigmentation even at 72 months,” Dr. Parsad added, though he called for prospective long-term studies to confirm these findings.
“MKTP has provided hope for many vitiligo patients . . . as its success rate can reach up to 90% repigmentation in patients with stable disease,” Dr. Bassel Mahmoud, of the Vitiligo Clinic and Research Center at the University of Massachusetts in Worcester told Reuters Health in an email.
“This study,” he added, “emphasizes even more the efficiency of this procedure, showing that its success is not only temporary, but also extends long term (up to 72 months), leading to a high degree of patient satisfaction.”
The study was partially supported by the Shahani Foundation and Multicultural Dermatology Fund at Henry Ford Hospital.
SOURCE: https://bit.ly/2t363aT
J Am Acad Dermatol 2017.
(c) Copyright Thomson Reuters 2017. Click For Restrictions - https://about.reuters.com/fulllegal.asp
